再生障碍性贫血的诊断治疗进展

Progress of diagnosis and treatment for aplastie anemia

随着分子生物学技术的发展，有关再生障碍性贫血（再障）的研究热点转向细胞遗传学，着力于探讨染色体及基因异常对再障的疗效影响。研究发现特定染色体及基因异常会对再障预后的诊断产生影响。另一方面，再障的首选治疗仍是根据不同情况选择免疫抑制治疗或骨髓移植，针对T细胞的特异性抗体正在研究中且疗效肯定。通过完善诊断分型和发展治疗手段，再障患者的生存率将继续提高。

As the technique of molecular biology developed, the research of aplastic anemia turns to the eytogenetical level. Scientists focused on investigating the relationship between the mutation of gene or chromosome and the curative effect of aplastie anemia. The results show that abnormality of particular chromosome or gene will cause different outcome. On the other hand,the first line therapy of aplastie anemia is still IST or HSCT according to the different situation. The antibody special for T cell is still in studying, and the effect shows well.Through the typing diagnosis consummated,the treating method developed,tbe survival rate of the patient with aplastic anemia will be advanced.